Published Date: 11/01/2022
Expiration Date: 02/22/2025
Hepatitis C virus (HCV) is the most common blood-borne viral infection, with an estimated 2.4 million people living with HCV in the United States alone. This course will review the most up to date information on how to effectively treat HCV and will discuss eligibility, recommended regimens and on-treatment monitoring for simplified HCV treatment. Additionally, this course will describe how to design a therapeutic regimen and monitoring plan for the treatment of HCV, review clinically important adverse effects, contraindications, and drug-drug interactions associated with medications used in the treatment of HCV as well as identify when HCV therapy prior authorization is required.
Andrew Aronsohn is an Associate Professor of Medicine in the Center for Liver Diseases at the University of Chicago Medical Center and is the program director for the Gastroenterology fellowship at the University of Chicago. Dr. Aronsohn is the co-principal investigator of HepCCATT, an initiative to diagnose, link to care and treat HCV in the Chicago area. This project utilizes telehealth technology to expand HCV management into the primary care setting. In addition, Dr. Aronsohn is a co-chair of the AASLD / IDSA HCV guidance and was a member of National Academies of Medicine committee which wrote “A National Strategy for the Elimination of Hepatitis B and C”. He also has a busy clinical practice, which includes both general and transplant hepatology.